| 貨號(hào) | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S81069-10mg |
99.7% | ￥130.00 | 9 | - | - | - |
|
S81069-50mg |
99.7% | ￥450.00 | 9 | - | - | - |
|
S81069-100mg |
99.7% | ￥650.00 | 5 | - | - | - |
|
S81069-200mg |
≥99% | ￥1100.00 | 貨期：2-3天 | - | - | - |
|
Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research
| 產(chǎn)品描述： | Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | MMP-9;RAAS | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Robinson DM, et al. Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure. Drugs. 2007;67(9):1359-78. 2. Yamamoto D, et al. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 2007 Dec;43(6):670-6. | ||||||||||||||||||||
| 溶解性： | H2O : 50 mg/mL (113.15 mM; Need ultrasonic) DMSO : 50 mg/mL (113.15 mM; Need ultrasonic) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營許可證（不帶存儲(chǔ)）
營業(yè)執(zhí)照(三證合一)
北京